Fig. 6.

HBA1(120–132) inhibits HIV-1 production. a Schematic depiction of virus production and treatment procedure. 15 min before transfection HEK293T cells are treated with HBA1(120–132) or BafA1 (Bafilomycin A1, 250 nM). Cells are then transfected with a pro-viral construct and medium is changed 16 h post transfection. Cells are re-treated with HBA1(120–132) 16 h and 24 h post transfection. After 48 h, supernatant (SN) is transferred to reporter cells (TZM-bl) and 2 days post infection reporter cells are analyzed, either via β-galactosidase assay or flow cytometry. Additionally, the supernatant is analyzed for the presence of p24 capsid protein. b Infectious virus yields as assessed by GFP flow cytometry of TZM-bl cells infected with SN from HEK293T transfected with a lentiviral vector, VSV-G, HIV-1 rev and gag/pol and treated as in (a). The number of infected (GFP +) cells was normalized to water control. Bars represent the mean of n = 3–6 ± SEM. c Infectious virus yields of HEK293T cells transfected with indicated primary transmitted founder (TF) HIV infectious molecular clones as assessed by β-galactosidase assay of TZM-bl 72 h post infection. Treatment with HBA1(120-132) as in (a). BafA1 (Bafilomycin A1, 250 nM). Bars represent the mean of n = 3 ± SEM. d ELISA quantifying HIV-1 48 h post transfection p24 in the supernatant of HEK293T transfected with indicated pro-viral constructs and treated with different amounts of HBA1(120–132). Bars represent mean of n = 3 ± SEM. b, c Student’s t-test with Welch correction. d Ratio paired t test. *p < 0.05; **p < 0.01; ***p < 0.001